Is LL-37 Better Than Cathelicidin? (Mechanism Explained)

Most questions about whether LL-37 is 'better than' cathelicidin stem from a fundamental misunderstanding of peptide biochemistry. LL-37 is not an alternative to cathelicidin. It is the functional product derived from the inactive precursor protein hCAP-18 (human cationic antimicrobial protein), which researchers refer to as cathelicidin. When proteinase 3 cleaves the 103-residue propeptide domain from hCAP-18 during neutrophil activation, the remaining 37-amino-acid C-terminal fragment becomes LL-37, named for its two N-terminal leucine residues. The question isn't which is superior. It's understanding that one is the precursor and the other is the active form that performs antimicrobial and immunomodulatory functions throughout the body.

Our team works directly with laboratories conducting peptide research across immune function, wound healing, and antimicrobial applications. The distinction between hCAP-18 and LL-37 matters operationally because only the cleaved, active LL-37 fragment exhibits the biological activity researchers seek. The intact cathelicidin precursor does not.

Is LL-37 better than cathelicidin?

LL-37 is not 'better than' cathelicidin. It is the 37-amino-acid bioactive fragment cleaved from the cathelicidin precursor protein hCAP-18. Cathelicidin refers to the entire gene family and the inactive propeptide; LL-37 is the functional antimicrobial peptide released after enzymatic cleavage by proteinase 3. The parent protein hCAP-18 has no antimicrobial activity until converted into LL-37 through neutrophil degranulation or epithelial cell processing.

The Direct Answer: LL-37 Is the Active Form of Cathelicidin

The confusion arises because 'cathelicidin' is both a gene family name and shorthand for the precursor protein. Human cathelicidin. Encoded by the CAMP gene. Produces hCAP-18, an 18-kilodalton protein stored in neutrophil granules and epithelial cells. hCAP-18 remains inactive until proteolytic cleavage by proteinase 3 (in neutrophils) or kallikreins (in epithelial tissue) releases the C-terminal 37-residue peptide LL-37. That cleaved fragment is what performs antimicrobial killing, modulates inflammation, recruits immune cells, and promotes angiogenesis. This article covers the enzymatic conversion pathway, the structural differences that confer activity, and what the distinction means for laboratory applications and supplementation claims.

hCAP-18 Versus LL-37: Structural and Functional Distinctions

hCAP-18 is a 134-amino-acid precursor protein with two domains: the conserved cathelin-like domain (residues 1–97) and the C-terminal antimicrobial domain (residues 98–134, which becomes LL-37 after cleavage). The cathelin domain stabilizes the molecule during storage but contributes no antimicrobial activity. When neutrophils degranulate during infection or tissue damage, serine protease 3 cleaves the bond between residues 97 and 98, releasing LL-37 into the extracellular environment. The released peptide adopts an alpha-helical conformation in membrane-mimetic environments, allowing it to insert into bacterial membranes and disrupt lipid bilayers. The primary mechanism behind its broad-spectrum antimicrobial activity against gram-positive bacteria, gram-negative bacteria, fungi, and enveloped viruses.

The structural shift from linear precursor to amphipathic helix is what confers function. LL-37 contains both hydrophobic and cationic residues arranged so that one face of the helix interacts with negatively charged bacterial membranes while the hydrophobic face inserts into the lipid core. hCAP-18 cannot adopt this conformation while the cathelin domain remains attached. The propeptide sterically blocks membrane insertion. Research published in the Journal of Biological Chemistry demonstrated that synthetic hCAP-18 showed no antimicrobial activity against Staphylococcus aureus or Escherichia coli, while LL-37 exhibited minimum inhibitory concentrations (MIC) of 2–8 micrograms per milliliter against the same strains.

The Enzymatic Cleavage Pathway That Activates Cathelicidin

LL-37 generation occurs through distinct pathways depending on tissue type. In neutrophils, proteinase 3. Stored in azurophil granules alongside hCAP-18. Cleaves the precursor during degranulation triggered by bacterial lipopolysaccharide, cytokines, or complement activation. Epithelial cells in the respiratory tract, gastrointestinal mucosa, and skin express kallikrein proteases (KLK5, KLK7, KLK14) that process cathelicidin extracellularly after secretion. Dysregulation of this cleavage cascade underlies multiple disease states: patients with rosacea overproduce KLK5, leading to excessive LL-37 generation and chronic inflammation, while individuals with Morbus Kostmann (a severe congenital neutropenia) produce normal hCAP-18 but lack the neutrophil elastase required for processing, resulting in recurrent bacterial infections despite adequate precursor levels.

Gastricsin. An aspartic protease active at pH 2–3 in the stomach. Also cleaves hCAP-18, producing fragments distinct from LL-37 with altered antimicrobial spectra. This alternate processing generates shorter peptides (LL-29, LL-32) with reduced activity against gram-negative bacteria but enhanced fungicidal properties. The cleavage specificity explains why oral supplementation with intact cathelicidin precursors cannot replicate systemic LL-37 effects. Gastric and intestinal proteases degrade the molecule into non-functional fragments before absorption.

Comparison: hCAP-18 Precursor vs LL-37 Active Peptide

This table summarizes the functional and structural differences between the inactive cathelicidin precursor and its bioactive cleavage product.

Key Takeaways

• LL-37 is the 37-amino-acid bioactive fragment cleaved from the 134-residue cathelicidin precursor protein hCAP-18. Not a competing molecule.
• hCAP-18 has no antimicrobial or immunomodulatory activity until proteinase 3 or tissue kallikreins remove the N-terminal cathelin domain.
• LL-37 adopts an amphipathic alpha-helical structure that allows membrane insertion and lipid bilayer disruption, conferring activity against bacteria, fungi, and enveloped viruses.
• Minimum inhibitory concentrations for LL-37 range from 2–8 micrograms per milliliter against common pathogens, while uncleaved hCAP-18 shows no measurable antimicrobial effect.
• Dysregulation of the cleavage pathway. Either overproduction (rosacea) or deficient processing (Morbus Kostmann). Causes distinct clinical pathologies despite normal precursor expression.
• Research applications require synthetic LL-37 because intact cathelicidin must undergo enzymatic processing to generate functional peptide.

What If: LL-37 and Cathelicidin Scenarios

What If I See Products Labeled 'Cathelicidin Supplements' — Are They Effective?

Avoid them. Oral cathelicidin supplements contain either hCAP-18 precursor protein or bovine-derived cathelicidin analogues, neither of which survives gastric digestion intact. Pepsin and gastricsin in the stomach cleave the peptide into fragments with no antimicrobial activity, and intestinal proteases further degrade any remaining structure before absorption. No published pharmacokinetic study has demonstrated detectable plasma LL-37 elevation after oral hCAP-18 administration. The bioactive LL-37 peptide itself would also be degraded orally. Functional delivery requires parenteral administration or topical application to intact epithelial barriers.

What If Research Protocols Call for 'Cathelicidin' — Which Form Should Be Used?

Use synthetic LL-37 unless the study specifically investigates proteolytic processing or precursor biology. When researchers refer to 'cathelicidin' in antimicrobial or immunomodulation assays, they mean the active LL-37 fragment. Not the hCAP-18 precursor. Real Peptides supplies research-grade LL-37 with validated sequence fidelity and endotoxin testing, eliminating the variability introduced by enzymatic cleavage steps. If your protocol requires physiologically relevant activation kinetics, you'll need both recombinant hCAP-18 and purified proteinase 3, but most functional assays bypass the precursor entirely.

What If Endogenous LL-37 Levels Are Low — Can Supplementation or Activation Strategies Help?

Systemic LL-37 deficiency occurs in specific genetic conditions (Morbus Kostmann) or acquired states (vitamin D deficiency, chronic malnutrition). Vitamin D upregulates CAMP gene transcription, increasing hCAP-18 production. Clinical trials showed 25-hydroxyvitamin D supplementation raised plasma cathelicidin levels by 40–80% in deficient individuals. Direct LL-37 supplementation for systemic immune support remains experimental; most therapeutic applications focus on topical wound-healing formulations or aerosolized delivery for respiratory infections. No FDA-approved LL-37 drug product exists as of 2026, though Phase II trials are ongoing for chronic wound management.

The Blunt Truth About 'LL-37 vs Cathelicidin' Marketing

Here's the honest answer: any product claiming LL-37 is 'superior to cathelicidin' or positioning them as competing options is either scientifically illiterate or deliberately misleading. They are not alternatives. LL-37 is the functional form of cathelicidin. It's like asking whether insulin is better than proinsulin: one is the inactive precursor, the other is what your body uses. The confusion is profitable for supplement companies selling 'cathelicidin activators' or 'precursor support formulas' with no evidence of efficacy. If you're evaluating a product that treats these as separate entities, you're looking at marketing, not biochemistry. For research purposes, the distinction matters operationally: labs order synthetic LL-37 because the precursor requires enzymatic processing before it does anything useful.

Why the Precursor-to-Product Relationship Matters for Research Applications

The enzymatic activation requirement creates experimental constraints researchers must account for. In vitro antimicrobial assays using cell-free systems require pre-cleaved LL-37. Adding hCAP-18 without proteinase 3 produces false-negative results because no active peptide forms. Conversely, studies investigating endogenous antimicrobial peptide responses in whole blood or tissue explants must measure both precursor and product to distinguish synthesis defects from cleavage defects. Patients with chronic granulomatous disease produce normal hCAP-18 but show impaired LL-37 generation due to defective neutrophil oxidative burst, which indirectly affects proteinase 3 release. Measuring only total cathelicidin misses the functional deficit.

Our team has observed this distinction matter significantly in wound-healing research. Chronic diabetic ulcers show elevated hCAP-18 in wound fluid but reduced LL-37, indicating a processing failure rather than synthesis failure. Topical application of synthetic LL-37 accelerated re-epithelialization in these wounds, while hCAP-18 application had no effect. The local protease environment was insufficient to activate the precursor. This finding underscores why therapeutic development focuses on the active peptide rather than precursor augmentation strategies. When selecting peptides for laboratory work, understanding whether your experimental question targets synthesis, cleavage, or effector function determines which molecular form you need. The full peptide collection at Real Peptides includes sequence-verified LL-37 designed specifically for functional assays where bioactivity must be immediate and independent of enzymatic processing.

Asking whether LL-37 is better than cathelicidin reflects confusion about the activation cascade, not a meaningful comparison between competing molecules. The precursor has one function: serving as a stable storage form until proteolytic cleavage releases the peptide that performs the immune work. For any application requiring antimicrobial activity, immunomodulation, or wound repair, LL-37 is the form that matters. The precursor is simply how the body keeps it inactive until needed.